RRoche Read More Genentech fenebrutinib cuts relapsing MS relapses 51%-59%2026-05-02 04/21/2026 – 07:15 PM Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
RRoche Read More Roche’s fenebrutinib cuts relapses in MS amid safety concerns2026-04-22 Roche is hoping to bring the the first and only high-efficacy oral for both relapsing multiple sclerosis (RMS)…
RRoche Read More Roche fenebrutinib cuts RMS relapses 51%-59%2026-04-22 Roche (OTCQX: RHHBY) reported that investigational fenebrutinib met primary endpoints in Phase III…